239 related articles for article (PubMed ID: 23375817)
1. Potential coverage of a multivalent M protein-based group A streptococcal vaccine.
Dale JB; Penfound TA; Tamboura B; Sow SO; Nataro JP; Tapia M; Kotloff KL
Vaccine; 2013 Mar; 31(12):1576-81. PubMed ID: 23375817
[TBL] [Abstract][Full Text] [Related]
2. Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development.
Williamson DA; Smeesters PR; Steer AC; Morgan J; Davies M; Carter P; Upton A; Tong SY; Fraser J; Moreland NJ
BMC Infect Dis; 2016 Oct; 16(1):561. PubMed ID: 27733129
[TBL] [Abstract][Full Text] [Related]
3. Concerns for efficacy of a 30-valent M-protein-based Streptococcus pyogenes vaccine in regions with high rates of rheumatic heart disease.
Giffard PM; Tong SYC; Holt DC; Ralph AP; Currie BJ
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007511. PubMed ID: 31269021
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
[TBL] [Abstract][Full Text] [Related]
5. Seven-year surveillance of emm types of pediatric Group A streptococcal pharyngitis isolates in Western Greece.
Syrogiannopoulos GA; Grivea IN; Al-Lahham A; Panagiotou M; Tsantouli AG; Michoula Ralf René Reinert AN; van der Linden M
PLoS One; 2013; 8(8):e71558. PubMed ID: 23977078
[TBL] [Abstract][Full Text] [Related]
6. Group A streptococcal emm type prevalence among symptomatic children in Cape Town and potential vaccine coverage.
Engel ME; Muhamed B; Whitelaw AC; Musvosvi M; Mayosi BM; Dale JB
Pediatr Infect Dis J; 2014 Feb; 33(2):208-10. PubMed ID: 23934204
[TBL] [Abstract][Full Text] [Related]
7. Seven-year surveillance of north american pediatric group a streptococcal pharyngitis isolates.
Shulman ST; Tanz RR; Dale JB; Beall B; Kabat W; Kabat K; Cederlund E; Patel D; Rippe J; Li Z; Sakota V;
Clin Infect Dis; 2009 Jul; 49(1):78-84. PubMed ID: 19480575
[TBL] [Abstract][Full Text] [Related]
8. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
Gupta VK; Sekhar S; Dhanda V; Toor D; Kumar R; Chakraborti A
J Microbiol Immunol Infect; 2016 Jun; 49(3):352-8. PubMed ID: 25087198
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterisation of group A streptococcus isolates recovered from the north-west of Pretoria, South Africa.
Khosa XV; Kgasha O; Mabuza H; Moshe M; Engel K; Nchabeleng M
S Afr Med J; 2021 Apr; 111(5):487-490. PubMed ID: 34852893
[TBL] [Abstract][Full Text] [Related]
10. Streptococcal pharyngitis in schoolchildren in Bamako, Mali.
Tapia MD; Sow SO; Tamboura B; Keita MM; Berthe A; Samake M; Nataro JP; Onwuchekwa UO; Penfound TA; Blackwelder W; Dale JB; Kotloff KL
Pediatr Infect Dis J; 2015 May; 34(5):463-8. PubMed ID: 25356953
[TBL] [Abstract][Full Text] [Related]
11. Molecular Epidemiology of Noninvasive and Invasive Group A Streptococcal Infections in Cape Town.
Barth DD; Naicker P; Engel K; Muhamed B; Basera W; Mayosi BM; Dale JB; Engel ME
mSphere; 2019 Oct; 4(5):. PubMed ID: 31666314
[TBL] [Abstract][Full Text] [Related]
12. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review and Meta-analysis of the Prevalence of Group A Streptococcal
Salie T; Engel K; Moloi A; Muhamed B; Dale JB; Engel ME
mSphere; 2020 Jul; 5(4):. PubMed ID: 32669471
[TBL] [Abstract][Full Text] [Related]
14. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS.
Smeesters PR; Dramaix M; Van Melderen L
Vaccine; 2010 Jan; 28(4):883-5. PubMed ID: 19963033
[No Abstract] [Full Text] [Related]
15. Molecular biology of Group A
Brahmadathan NK
Indian J Med Microbiol; 2017; 35(2):176-183. PubMed ID: 28681803
[TBL] [Abstract][Full Text] [Related]
16. [Distribution of emm genotypes and antibiotic susceptibility of Streptococcus pyogenes strains: analogy with the vaccine in development].
Arslan U; Oryaşın E; Eskin Z; Türk Dağı H; Fındık D; Tuncer I; Bozdoğan B
Mikrobiyol Bul; 2013 Apr; 47(2):318-23. PubMed ID: 23621731
[TBL] [Abstract][Full Text] [Related]
17. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci.
Dale JB; Penfound TA; Chiang EY; Walton WJ
Vaccine; 2011 Oct; 29(46):8175-8. PubMed ID: 21920403
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
[TBL] [Abstract][Full Text] [Related]
19. Prospective surveillance of streptococcal sore throat in a tropical country.
Steer AC; Jenney AW; Kado J; Good MF; Batzloff M; Magor G; Ritika R; Mulholland KE; Carapetis JR
Pediatr Infect Dis J; 2009 Jun; 28(6):477-82. PubMed ID: 19483515
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of synthetic, M type-specific peptides as antigens in a multivalent group A streptococcal vaccine.
Bruner M; James A; Beall B; Carlone GM; Ades E; Johnson S; Guarner J; Sampson J
Vaccine; 2003 Jun; 21(21-22):2698-703. PubMed ID: 12798606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
